Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income towards Parent Company: 2017-2025

Historic Income towards Parent Company for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Income towards Parent Company fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.15%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Income towards Parent Company is -$39.3 million, which was down 13.05% from -$34.8 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Income towards Parent Company peaked at $207.3 million during Q1 2024, and registered a low of -$41.0 million during Q2 2022.
  • For the 3-year period, Protagonist Therapeutics' Income towards Parent Company averaged around $10.0 million, with its median value being -$33.2 million (2024).
  • As far as peak fluctuations go, Protagonist Therapeutics' Income towards Parent Company slumped by 335.45% in 2021, and later spiked by 714.80% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Income towards Parent Company (Quarterly) stood at -$37.2 million in 2021, then grew by 7.77% to -$34.3 million in 2022, then skyrocketed by 179.78% to $27.3 million in 2023, then spiked by 381.70% to $131.7 million in 2024, then dropped by 18.46% to -$39.3 million in 2025.
  • Its Income towards Parent Company stands at -$39.3 million for Q3 2025, versus -$34.8 million for Q2 2025 and -$11.7 million for Q1 2025.